CD274 and triple-negative breast carcinoma: In contrast, the combination of entinostat plus anti-PD-L1 antibodies (avelumab or atezolizumab) showed no clinical benefit compared to ICI alone in patients with low TMB, such as epithelial ovarian cancer, triple-negative breast cancer, and myelodysplastic syndrome (NCT02915523, NCT02708680, NCT02936752) [77–79].